Timing is everything for artemisinin action
Open Access
- 14 March 2013
- journal article
- editorial
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (13) , 4866-4867
Abstract
In Cambodia, the same region where chloroquine resistance developed in the 1950s, a significant delay in the Plasmodium falciparum parasite clearance rates to artemisinins has been persistently observed over the past 5 y, raising the specter of artemisinin “resistance” (1). The parasites in this region have imprints of genetic selection associated with the delay in parasite clearance rates measured by serial patient blood films (2⇓–4). However, the traditional continuous inhibition concentration 50% (IC50) drug assays measured directly with parasites from patient’s blood indicate no significant difference in IC50s (1, 5). In PNAS, Klonis et al. (6) expand upon our knowledge of intraerythrocytic action of artemisinins, in a tour de force of P. falciparum in vitro culture work, by exposing three laboratory isolates to short 1-, 2-, 4-, or 6-h pulses of artemisinins every hour throughout the 48-h life cycle to determine pulse drug IC50. An important unique finding is that an early ring stage that is less than 8-h-old is hypersensitive to artemisinins, and that intrinsic differences preexist among decades-old laboratory P. falciparum isolates not thought to be exposed to the artemisinin drugs before isolation. In an earlier report by Klonis et al. (7), as well as a report by ter Kuile et al. (8), the timing of artemisinin action had been demonstrated to coincide with the onset of hemoglobin ingestion during the late-ring or early trophozoite stages. This experimental window of artemisinin duration of action during the 48-h P. falciparum erythrocyte life cycle is longer than quinoline drugs, such as quinine, mefloquine, or lumefantrine, which inhibit heme crystallization (8). Many malariologists believe artemisinins work after iron activation to induce carbon-centered radical damage of nearby proteins for low 1- to 10-nM inhibition of Plasmodium trophozoite stages, … [↵][1]1E-mail: dsulliva{at}jhsph.edu. [1]: #xref-corresp-1-1Keywords
This publication has 19 references indexed in Scilit:
- Artesunate, a potential drug for treatment of Babesia infectionParasitology International, 2010
- High Heritability of Malaria Parasite Clearance Rate Indicates a Genetic Basis for Artemisinin Resistance in Western CambodiaThe Journal of Infectious Diseases, 2010
- Population pharmacokinetics of artesunate and amodiaquine in African childrenMalaria Journal, 2009
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Malaria-Infected Mice Are Cured by a Single Oral Dose of New Dimeric Trioxane Sulfones Which Are Also Selectively and Powerfully Cytotoxic to Cancer CellsJournal of Medicinal Chemistry, 2009
- Artemisinin-Resistant Mutants of Toxoplasma gondii Have Altered Calcium HomeostasisAntimicrobial Agents and Chemotherapy, 2007
- In Vitro Inhibition of Toxoplasma gondii by Four New Derivatives of ArtemisininAntimicrobial Agents and Chemotherapy, 2006
- A Medicinal Chemistry Perspective on Artemisinin and Related EndoperoxidesJournal of Medicinal Chemistry, 2004
- Artemisinins target the SERCA of Plasmodium falciparumNature, 2003
- Plasmodium falciparum: In Vitro Studies of the Pharmacodynamic Properties of Drugs Used for the Treatment of Severe MalariaExperimental Parasitology, 1993